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ABSTRACT 
 
Bioequivalence studies are the usually accepted method to determine the therapeutic equivalence of two drug 
products. Because in-vivo bioequivalence studies are time consuming and expensive to conduct, major 
regulatory authorities have introduced biowaivers for some selected medicines belonging to BCS class 1 and 
III drugs. Comparative dissolution tests are used in biowaiver procedure to waiver the bioequivalence 
requirement. We performed this study to see whether two brands of paracetamol tablets are bioequivalent 
using the in-vitro methodology. In the first stage of this research study, British Pharmacopeia 2012 quality 
tests were performed on the two selected paracetamol tablet products  to determine whether they are 
pharmaceutically equivalent. In the second stage in-vitro equivalence of the two products was determined 
using the biowaiver testing procedure given by the World Health Organization. Dissolution profiles were 
generated at pH values, 1.2, 4.5 and 6.8. Results were compared through two model independent methods, 
difference factor (f1) and similarity factor (f2). The two paracetamol tablet products tested, complied with all 
the quality requirements of the British Pharmacopeia 2012. For the two products, the difference factor (f1) 
was below the 15 and similarity factor (f2) was above the 50 in all dissolution test conditions.  These results 
confirm that the two products are pharmaceutically equivalent. The test product is also bioequivalent to the 
reference product in-vitro, and therefore they can be interchangeable during clinical use. This study shows 
that in-vivo bioequivalence testing can be waived using the in-vitro method, for some pharmaceutical 
products such as paracetamol tablets. 
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1.  INTRODUCTION 
 
Paracetamol is an over the counter medication 
used widely as an analgesic agent for 
symptomatic management of mild to moderate 
pain. Also, it has excellent antipyretic 
properties and is used to reduce the body 
temperature in patients with fever (Kalantzi et 
al., 2006; Ellis et al., 2002). In Sri Lanka, as 
well as in other countries many brands and 
generics of paracetamol (500 mg) tablets are 
available. These are formulated to be 
pharmaceutically equivalent to each other. 
Pharmaceutically equivalent drug products 
contain same molar amount of the same active 
pharmaceutical ingredient in the same dosage 
form if they meet comparable standards and 
administered by the same route. Pharmaceutical 
equivalence does not necessarily imply 
similarity of therapeutic effect. Therefore, there 
are concerns when it comes to substituting one 
brand of a pharmaceutically equivalent drug 
product to another in clinical practice (WHO, 
2006; USP, 2012). 
 
Pharmaceutically equivalent drug 
products should be bioequivalent (or 
therapeutically equivalent) to each other to be 
given interchangeably during the clinical 
practice.  Two drug products are bioequivalent 
if they are pharmaceutically equivalent and 
their effects can be expected to be essentially 
the same after administration of the same molar 
dose under the same conditions. Bioequivalence 
(BE) testing is a comparative test, which uses 
specified criteria for comparison and have 
predetermined BE limits for such criteria 
(HHS/FDA, 2003; WHO, 2006a). 
 
There are several in-vivo and in-vitro 
approaches to determine the equivalence of two 
pharmaceutically equivalent drug products. 
These approaches include pharmacokinetic 
studies, pharmacodynamic studies, comparative 
clinical trial studies and in-vitro dissolution 
studies (HHS/FDA, 2003; WHO, 2006) 
Because in-vivo BE studies are time consuming 
and expensive to conduct, major regulatory 
authorities such as United States Food and Drug 
Administration (US-FDA) and World Health 
Organization (WHO) have introduced 
biowaivers. The biowaiver approach, waives in-
vivo BE studies by the means of comparative 
in-vitro dissolution test and it’s based on the 
Biopharmaceutical Classification System 
(BCS). There are only several pharmaceutical 
formulations which are currently being 
considered for biowaivers. According to the 
WHO, paracetamol is a BCS class I active 
pharmaceutical ingredient (highly soluble and 
highly permeable) thus making it eligible to be 
considered for biowaivers (HHS/FDA, 2003; 
WHO, 2006). 
 
In biowaiver studies, comparison of 
dissolution profiles is done for two 
pharmaceutically equivalent products under 
identical conditions. In order to compare the 
dissolution profiles, similarity factor (f2) and 
difference factor (f1) are used. The f1 calculates 
the relative error based on the percent 
difference between the two dissolution profiles. 
 
f1 ={[ |Rt-Tt|]/ Rt]}.100.
n
t=1
n
t=1  
  
The f2 calculates the percent similarity 
between the two dissolution profiles. 
 
f2=50.log{[1+(
1
n
)  Rt-Tt 
2
]nt=1
-0.5
.100} 
 
In above equations, n is the number of 
sampling time points used to draw a drug 
dissolution profile, Rt is dissolution value of the 
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reference batch at time t and Tt is dissolution 
value of the test batch at time t. 
 
Generally a f1 value up to 15 (0-15) and 
a f2 value greater than 50 (50-100) indicates the 
equivalence of the two dissolution profiles 
between two pharmaceutical products. A f2 of 
50 represents an average 10 % difference of 
drug release at all sampling time points, while a 
f2 of 100 represents zero average difference of 
drug release at all sampling time points 
(HHS/FDA, 1997). 
 
This study was carried out to 
investigate the in-vitro equivalence of selected 
two paracetamol 500 mg tablet products, taking 
the market leader product as the reference 
product and the brand currently utilized in the 
public sector as the test product. In order to 
declare the pharmaceutical equivalency of these 
two paracetamol tablet products quality testing 
methods of British Pharmacopeia 2012 (BP 
2012) paracetamol tablet monograph were used. 
 
2       MATERIALS AND METHODS 
 
2.1   Materials 
 
Reference paracetamol tablets (Panadol) was 
obtained as a donation for the purpose of the 
research study from GlaxoSmithKline, Sri 
Lanka. Test paracetamol tablets (SPMC 
Paracetamol) were obtained from the Lady 
Ridgeway Hospital for Children via request 
from the Medical Supplies Division, Ministry 
of Health, Sri Lanka. Paracetamol working 
standard, 4-aminophenol, and 
tetrabutylammonium hydroxide were obtained 
as a donation from Astron Limited, Sri Lanka 
for the paracetamol related substance test. All 
the chemicals used for the research study were 
analytical reagent grade. For the related 
substance test HPLC graded chemicals were 
used. 
 
2.2 Quality Testing for Two Products of 
Paracetamol 500 mg Tablets According 
to the BP 2012 
 
Uniformity of mass: Uniformity of mass test 
was performed on CAS CAY 120 electronic 
balance. Three trials were conducted for the 2 
products separately (BP, 2012). 
 
Assay: Analysis of paracetamol was done 
according to the BP 2012 Paracetamol tablets 
monograph assay using CAS CAY 120 
electronic balance and JASCO V-560 UV/VIS 
spectrophotometer. Three trials were performed 
for each product (BP, 2012). 
 
Friability of paracetamol tablets: The 
friability of randomly selected eleven tablets 
were investigated using EP 420A-FR Electronic 
balance and ERWEKA Friability Tester. Three 
trials were performed for each product (BP, 
2012).  
 
Resistance to crushing of paracetamol 
tablets: Hardness of randomly selected 10 
tablets was investigated using ERWEKA 
hardness tester. Three trials were performed for 
each tablet product [8]. 
 
Dissolution: A volume of 900 ml (± 1 %) of 
phosphate buffer pH 5.8 (Prepared according to 
the BP 2012) was placed in the each vessel of 
the PHARMA TEST dissolution apparatus. 
Dissolution medium was equilibrated to 37 ± 
0.5 
0
C. Six tablets were randomly selected for 
the dissolution test. Prior to commencement of 
the test, care was taken to exclude air bubbles 
from the surface of the tablets. Paddles were 
rotated at 50 revolutions per minute, for 45 
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minutes. Sample medium was collected at 5, 
10, 15, 20, 30, 45 minutes from all 6 vessels 
using the auto sampler system. One milliliter of 
the collected samples was diluted to 10.00 ml 
with 0.1M sodium hydroxide. One milliliter of 
the resulting solutions were diluted up to 10.00 
ml with 0.1M sodium hydroxide. This dilution 
procedure was carried out for all 36 samples 
and absorbance was measured using VARIAN 
CARY-50 Bio UV/VIS spectrophotometer at 
257 nm using 0.1M sodium hydroxide in the 
reference cell. Percentage release of the drug 
from paracetamol tablets was determined. 
Dissolution profile was plotted for each tablets. 
The same procedure was followed for the two 
tablet products separately. 
 
Related substance test: Analysis of 4-
aminophenol content in the paracetamol tablets 
was done using high performance liquid 
chromatography (SHIMADZU HPLC machine 
and C8 stainless steel column with dimension of 
25 cm X 4.6 mm) according to the BP 2012 
paracetamol tablets related substance test (BP, 
2012). 
 
Following solutions were prepared 
immediately before the test was started and 
covered with aluminum foil in order to protect 
those from light. 
 
Solution - 1: Powdered tablet from each 
product containing 0.2 g of paracetamol was 
dispersed in 8.00 ml of the mobile phase using 
sonicator. Sufficient volume of mobile phase 
was added to produce 10.00 ml of the solution. 
Resulting solution was mixed well and filtered. 
Separate solutions have been made for the two 
paracetamol products using above procedure.  
 
Solution – 2: Volume of 1.00 ml of solution 1 
has been diluted to 20.00 ml with mobile phase. 
Volume of 1.00 ml of this solution has been 
diluted up to 20.00 ml with mobile phase.  
 
Solution – 3: Volume of 100.00 ml containing 
0.002 % w/v 4-aminophenol in the mobile 
phase and volume of 100.00 ml containing 
0.002 % w/v paracetamol reference standard in 
the mobile phase were mixed together to 
produce 200 ml of the solution. 
  
Preparation of mobile phase and 
adjustment of mobile phase parameters were 
done as follows. 
 
Volume of 1000.0 ml of HPLC graded 
methanol containing 4.60 g of a 40 % v/v 
solution of tetrabutylammonium hydroxide was 
made and filtered using pore size of 0.45 
micrometer cellulose acetate filter paper. 
Volume of 1000.0 ml of 0.05 M disodium 
hydrogen orthophosphate (analytical reagent 
grade of commerce) and 1000.0 ml of 0.05 M 
sodium dihydrogen orthophosphate (analytical 
reagent grade of commerce) were mixed 
together and filtered using pore size of 0.45 
micrometer cellulose acetate filter paper. In 
order to make the 1000 ml of mobile phase, 250 
ml of methanol containing 1.15 g of 40 %v/v 
solution of tetrabutylammonium hydroxide 
were mixed with 750 ml of the mixture of 
0.05M sodium dihydrogen orthophosphate and 
disodium hydrogen orthophosphate. Mobile 
phase flow rate was adjusted to 1 ml per minute 
at a temperature of 35 
0
C. Volume ratio has 
been adjusted as 1 volume of methanol contains 
40 % v/v solution of tetrabutylammonium 
hydroxide to 3 volume of phosphate buffer. 
Detection wavelength was adjusted to 245 nm. 
 
Injection of prepared solutions and results 
interpretation of obtained chromatograms were 
done according to BP 2012. 
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2.3   Determination of in-vitro Equivalence of 
Paracetamol 500 mg Tablets  
 
For each product at each pH (pH 1.2 
HCl, pH 4.5 acetate buffer and pH 6.8 
phosphate buffer), a volume of 900 ml (±1 %) 
of the dissolution media was placed in each and 
every vessel of the PHARMA TEST dissolution 
apparatus. Dissolution medium was equilibrated 
to 37 ± 0.5 
0
C. Twelve tablets were randomly 
selected for the dissolution test. Prior to the 
commencement of the test care was taken to 
exclude air bubbles from the surface of the 
tablets. Paddles were rotated at 75 revolutions 
per minute, for 45 minutes. Samples of 
dissolution medium were collected at 5, 10, 15, 
20, 30, 45 minutes from all 6 vessels using auto 
sampler system. The dilution procedure 
described in the BP 2012 was carried out to 
dilute all the 72 samples and their absorbance 
was measured using VARIAN CARY-50 Bio 
UV/VIS spectrophotometer according to the 
procedure describe under the section 2.2 
dissolution test. Average percentage release of 
the drug from paracetamol tablets in each time 
point was determined in order to apply those 
values for the calculation of f2 and f1. 
 
3 RESULTS AND DISCUSSION 
 
3.1 Quality Testing for Two Products of 
Paracetamol 500 mg Tablets According 
to the BP 2012 
 
Uniformity of mass: Results of uniformity of 
mass test for both products are illustrated in 
Table 1. According to the BP uniformity of 
mass test, for tablets weighing more than 250 
mg, permissible percentage deviation of the 
mass is 5%. In order to comply for the 
requirement of uniformity of mass test, more 
than 2 of the individual masses should not 
deviate from the average mass by more than the 
percentage deviation, and none should deviate 
more than twice the percentage (BP, 2012). 
Thus both products complied with the 
requirements for BP uniformity of mass test. 
 
Assay: Results achieved from analysis of active 
ingredient (paracetamol) in both products are 
given in Table 1. As per BP 2012 
specifications, the content should not be less 
than 95% and not more than 105% of labeled 
amount of the tablets (BP, 2012). Results 
indicate the reference product assay value is in 
the acceptable limits. Despite the second assay 
trial failing by 0.6%, the average content of the 
labeled amount of the test product is in the 
accepted BP range.  
 
Friability of paracetamol tablets: Friability 
test is to ensure that tablets possess a suitable 
mechanical strength to avoid abrasion, 
crumbling or breaking on handling or 
subsequent processing. Results achieved from 
the friability test in both products are given in 
Table 1. A BP 2012 specification for friability 
is a maximum loss of mass not greater than 1.0 
% (BP, 2012). Thus both products comply with 
the specifications of the BP 
 
Resistance to crushing of tablets: The 
hardness or crushing strength of tablets assesses 
the ability of tablets to withstand handling 
without fracturing or chipping. The results were 
interpreted as average hardness of 10 tablets, 
minimum hardness value, and maximum 
hardness value according to the BP (BP, 2012). 
Results achieved from hardness test for both 
products are given in Table 1. 
Dissolution: Dissolution profiles for the two 
products are shown in Figure 1 and Figure 2. 
According to the harmonized dissolution 
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criteria, no unit must release the drug product 
less than 80 % of the labeled amount in 45 
minutes. Hence both products comply with the 
BP dissolution test. 
 
Related Substance Test: The major impurity 
of paracetamol raw material is 4-aminophenol. 
The quantity of 4-aminophenol present in a 
paracetamol tablet must be strictly controlled as 
4-aminophenol has nephrotoxic and teratogenic 
effects (Ca˘linescu et al., 2012). Because of the 
resolution factor between the two principal 
peaks of the chromatogram obtained with the 
reference solution is 5.587 which is greater than 
4.0, the HPLC test was accepted as a valid test 
according to BP 2012. 
  
The chromatogram obtained with 
solution - 1 for reference product, the area of 
the peak correspond to 4-aminophenol is not 
greater than area of corresponding peak of 4-
aminophenol in the chromatogram obtained 
with standard solution - 3. The chromatogram 
obtained with solution - 1 for test product, the 
area of the peak corresponds to 4-aminophenol 
is not greater than area of corresponding peak 
of 4-aminophenol in the chromatogram 
obtained with standard solution - 3.  No other 
impurity (peaks correspond to impurities in 
solution - 1 of both products) is greater than the 
area of the principal peak obtained with 
solution - 2 of both products. Thus the levels of 
4-aminophenol in both the paracetamol tablet 
products were below the level specified in the 
BP. 
 
 
 
Figure 1. Dissolution profiles of six tablets of 
the reference product at pH 5.8 phosphate 
buffer 
 
 
 
Figure 2. Dissolution profiles of six tablets of 
the test product at pH 5.8 phosphate buffer 
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TABLE 1. Results of the Uniformity of Mass, Assay, 
Friability Test and Hardness Test (Test for Resistant to 
Crushing of Tablets).  
 
Test Reference Product Test Product 
Trial 
1 
Trial 2 Trial 3 Trial 1 Trial 2 Trial 
3 
Uniformity 
of mass  
 
Accepted 
mass 
deviation 
range (g) 
 
 
 
 
0.564
7-
0.624
1 
 
 
 
0.5612
-
0.6203 
 
 
 
0.5637
-
0.6230 
 
 
 
0.5435
-
0.6007 
 
 
 
0.5969
-
0.5401 
 
 
 
0.5436
-
0.6008 
Number of 
tablets 
outside the 
deviation 
range 
None None None None 2 None 
Assay  
 
Content of 
paracetamol 
as a 
percentage 
of labeled 
amount (%) 
 
 
103.7 
 
 
99.9 
 
 
101.1 
 
 
97.2 
 
 
94.4 
 
 
96.6 
Friability 
test  
 
Percentage 
loss of mass 
(%) 
 
 
 
0.453
9 
 
 
 
0.0736 
 
 
 
0.0369 
 
 
 
0.1964 
 
 
 
0.0862 
 
 
 
0.5255 
Hardness 
test  
 
Average 
hardness 
(N) 
 
 
 
 
151 
 
 
 
148 
 
 
 
146 
 
 
 
130 
 
 
 
135 
 
 
 
131 
Minimum 
hardness 
(N) 
 
136 136 136 099 099 097 
Maximum 
hardness 
(N) 
156 156 154 148 148 148 
 
3.2 Determination of in-vitro Equivalence 
of Paracetamol 500 mg Tablets 
  
Dissolution tests (Table 2) were carried 
out in order to determine the in-vitro 
equivalence of two paracetamol tablet products 
adopting the biowaiver testing procedure 
proposed by the WHO. Dissolution profile 
comparison (Figure 3, Figure 4 and Figure 5) of 
the two paracetamol tablets (in all the three 
dissolution media) was done according to the 
recommendations given by US-FDA. 
Calculated values of f1 and f2 are given in   
Table 2.  
 
Because the f2 for all three dissolution 
media is within the range of 50-100 and the f1 
for all three dissolution media is within the 
range of 0-15 there is a similarity of dissolution 
profile of both products in all the three 
dissolution media. 
 
 
Figure 3. Dissolution profiles of paracetamol tablets 
in pH 1.2 HCl media 
 
 
 
Figure 4. Dissolution profiles of paracetamol tablets 
in pH 4.5 acetate buffer 
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Figure 5. Dissolution profiles of paracetamol 
tablets in pH 6.8 phosphate buffer 
 
TABLE 2. Dissolution Tests Carried Out In 
Order to Determine the in-vitro Equivalence of 
Paracetamol Tablets and Calculated Similarity 
Factor (f2) and Difference Factor (f1) . 
 
Test  Products Number 
of 
tablets 
Dissolution 
media 
f1 f2 
1 Reference 12 pH 1.2 HCl 
Solution 
7.971 
 
56.18 
Test 12 pH 1.2 HCl 
Solution 
2 Reference 12 pH 4.5 Acetate 
Buffer 
10.18 51.17 
 
Test 12 pH 4.5 Acetate 
Buffer 
3 Reference 12 pH 6.8 
Phosphate 
Buffer 
5.554 51.44 
Test 12 pH 6.8 
Phosphate 
Buffer 
 
4.  CONCLUSION 
 
Reference paracetamol tablets comply with all 
the BP 2012 quality specifications such as the 
uniformity of mass, assay, dissolution, related 
substances test, hardness test, and friability test. 
Test paracetamol tablets also comply with all 
the BP quality specifications. It can be 
concluded that the test product is 
pharmaceutically equivalent to the reference 
product. 
 
In-vitro equivalence test was carried 
out as the second stage of the research study. 
Similarity factor was calculated for all the three 
dissolution media. Similarity factor is 56.18 for 
the pH 1.2 HCl solution, 51.17 for the pH 4.5 
acetate buffer and 51.44 for the pH 6.8 
phosphate buffer. Since the similarity factor is 
within the accepted range (50 - 100) for profile 
similarity in all three media, the test 
paracetamol tablet brand demonstrates 
equivalent dissolution to the reference 
paracetamol tablet brand in-vitro. Thus it can be 
concluded that the two products can be 
substituted with each other during the clinical 
practice. Results of this study indicates the 
possibility of post marketing evaluation of 
pharmaceutically equivalent products in-vitro 
as a substitute for in-vivo bioequivalence 
testing. 
 
REFERENCES 
 
ELLIS, F. (2002). Paracetamol - a curriculum 
resource. Royal Society of Chemistry. 
BRITISH PHARMACOPOEIA COMMISSION 
(2012). British Pharmacopeia. Stationary 
office, London.  
CALINESCU, O., BADEA, IA., VLA˘DESCU, 
L., MELTZER, V AND PINCU, E. (2012). 
HPLC Separation of Ac-etaminophen and 
its Impurities Using a Mixed-mode 
Reversed-Phase/Cation Exchange 
Stationary Phase. Journal of 
Chromatographic Science. 50, 335–342.  
 HHS/FDA GUIDANCE FOR INDUSTRY 
(2003). Bioavailability and Bioequivalence 
studies for Orally Administered Drug 
products-General Considerations. U.S. 
Department of Health and Human Services 
0.00
20.00
40.00
60.00
80.00
100.00
0 10 20 30 40 50A
v
er
ag
e 
p
er
ce
n
ta
g
e 
re
le
as
e 
(%
)
Time (minutes)
Average percentage release of Paracetamol 
(%) vs Time (minutes)
Reference
Test
Determination of in-vitro Equivalence of Paracetamol Tablets 
83 
Food and Drug Administration, Rockville, 
MD. 
HHS/FDA GUIDANCE FOR INDUSTRY 
(1997). Dissolution Testing of Immediate 
Release Solid Oral Dosage Forms. U.S. 
Department of Health and Human Service 
Food and Drug Administration, Rockville, 
MD. 
KALANTZI, L., REPPAS, C., DRESSMAN, 
JB., AMIDON, GL., JUNGINGER, HE., 
MIDHA, KK., SHAH, VP., 
STAVCHANSKY, SA AND BARENDS, 
DM. (2006). Biowaiver monographs for 
immediate release solid oral dosage forms: 
Acetaminophen (paracetamol). Journal of 
Pharmaceutical Science. 95, 4-14. 
WHO EXPERT COMMITTEE ON 
SPECIFICATIONS FOR 
PHARMACEUTICAL PREPARATIONS 
(2006). Annex 7: Multisource (generic) 
pharmaceutical products: guidelines on 
registration requirements to establish 
interchangeability. WHO technical report 
series, No. 937. World Health Organization, 
Geneva. 
WHO EXPERT COMMITTEE ON 
SPECIFICATIONS FOR 
PHARMACEUTICAL PREPARATIONS 
(2006). Annex 8: Proposal to waive in-vivo 
bioequivalence requirements for WHO 
Model List of Essential Medicine 
immediate-release, solid oral dosage forms. 
WHO technical report series, No. 937. 
World Health Organization Geneva.  
UNITED STATES PHARMACOPEIA 
CONVENTION (2012). United States 
Pharmacopeia. Rockville, MD. 
 
ACKNOWLEDGMENTS 
 
We would like to express our sincere gratitude 
to Mrs. Menike, Mrs. Chithra, and Mrs. Nisha 
and all the Pharmaceutical Chemistry 
Laboratory staff of the Department of 
Pharmacy and Department of Pharmacology, 
University of Colombo, Sri Lanka for the 
technical guidance. 
 
We would also like to thank Professor 
Sujatha Heage for giving us the opportunity to 
use the Sri Lanka Pharmaceutical Laboratory, 
Department of Chemistry, University of 
Colombo, Sri Lanka for this research study. We 
would offer our kind gratitude to Mr. Paasha 
and Ms. Sudheera (Laboratory staff of Sri 
Lanka Pharmaceutical Laboratory) for the 
technical guidance. I would also like thank to 
all the laboratory staff of Center for Analytical 
Research and Development, Department of 
Chemistry, University of Colombo, Sri lanka. 
 
 We would like to thank Mrs. Hemamali 
Tibbotumunuwa (Regulatory Affairs Manager, 
GlaxoSmithKline), Dr. Rathnasiri A. Hewage 
(Director, Lady Ridgeway Hospital for 
Children) and Dr. Parakrama Herath (Former 
general manager of Quality operations, 
Regulatory and Research, Astron Limited, Sri 
Lanka) for donating the samples of paracetamol 
tablets and chemicals for the research study. 
